-- AstraZeneca has shelved a plan to build a vaccine manufacturing plant in Speke, near Liverpool, valued at 450 million pounds ($558.7 million), after months of talks with British government officials about state investment, the Financial Times reports, citing a company statement and unnamed sources.
-- Keir Starmer's Labour government last year sought to reduce the amount of state support to 40 million pounds from 90 million pounds, but U.K. officials last month put forward an offer significantly higher than 40 million pounds, the FT says, citing unnamed sources.
-- The final offer was one of the factors influencing its decision to ditch the plan, AstraZeneca said, according to the FT.
Full story: https://tinyurl.com/5yxveb6e
Write to Cristina Gallardo at cristina.gallardo@wsj.com
(END) Dow Jones Newswires
January 31, 2025 11:07 ET (16:07 GMT)
Copyright (c) 2025 Dow Jones & Company, Inc.
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。